The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group
Mark S. Freedman(University of Ottawa), Harold Atkins(University of Ottawa), Hillard M. Lazarus(University Hospitals of Cleveland), Antonio Uccelli(Istituti di Ricovero e Cura a Carattere Scientifico), Francesco Frassoni(Ospedale Policlinico San Martino), Amit Bar‐Or(University of Pennsylvania), Neil Scolding(University of Bristol), Katarina Le Blanc(Karolinska University Hospital), Dimitrios Karussis, Shimon Slavin(Hadassah Medical Center)
Cited by 219
Related Papers
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
|New England Journal of Medicine|2016|1.9k